Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Usana Health SciencesSTU:USJ -1.56%67 Return-on-Tangible-Equity is 10.40% as of Mar. 2026, which is 60% below its 10-year median of 26.21. GuruFocus rates STU:USJ with a GF Score™ of 67/100 and a GF Value™ of €35.51 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,881 Consumer Packaged Goods companies, Usana Health Sciences ranks worse than 66.77% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Usana Health Sciences's annualized net income for the quarter that ended in Mar. 2026 was €24.1 Mil. Usana Health Sciences's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €231.5 Mil. Therefore, Usana Health Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 10.40%.
The historical rank and industry rank for Usana Health Sciences's Return-on-Tangible-Equity or its related term are showing as below:
STU:USJ'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.28 Med: 26.21 Max: 40.07
Current: 3.28
During the past 13 years, Usana Health Sciences's highest Return-on-Tangible-Equity was 40.07%. The lowest was 3.28%. And the median was 26.21%.
STU:USJ's Return-on-Tangible-Equity is ranked worse than 66.77% of 1881
companies
in the Consumer Packaged Goods industry
Industry Median: 7.78
vs STU:USJ: 3.28
Usana Health Sciences (STU:USJ) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Usana Health Sciences Return-on-Tangible-Equity Related Terms
Usana Health Sciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Usana Health Sciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Usana Health Sciences Return-on-Tangible-Equity Chart
STU:USJ vs NATR, ENHA, BYND: Return-on-Tangible-Equity Comparison
For the Packaged Foods subindustry, Usana Health Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Usana Health Sciences Return-on-Tangible-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Usana Health Sciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 10.40% mean?
Usana Health Sciences (STU:USJ) has a Return-on-Tangible-Equity of 10.40% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Usana Health Sciences and its competitors. This is 60% below median its historical median of 26.21. Over the past decade, Usana Health Sciences' Return-on-Tangible-Equity has ranged from 3.28 to 40.07. According to the industry distribution chart, Usana Health Sciences ranks #1256 out of 1881 companies in the Consumer Packaged Goods industry, placing it in the top 66.8%.
Is Usana Health Sciences' Return-on-Tangible-Equity too high?
Usana Health Sciences' current Return-on-Tangible-Equity of 10.40% is 60% below median its 10-year median of 26.21. Over the past 10 years, this metric has ranged from a low of 3.28 to a high of 40.07. The Consumer Packaged Goods industry median Return-on-Tangible-Equity is 7.78. Usana Health Sciences' value of 10.40% is 33.7% above this industry median. Based on the distribution chart, Usana Health Sciences ranks #1256 out of 1881 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Usana Health Sciences has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Usana Health Sciences' Return-on-Tangible-Equity compare to NATR and ENHA?
According to the Consumer Packaged Goods industry distribution chart, Usana Health Sciences ranks #1256 out of 1881 companies for Return-on-Tangible-Equity. This places Usana Health Sciences in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.78. Usana Health Sciences' value of 10.40% is 33.7% above this benchmark. Historically, Usana Health Sciences' own Return-on-Tangible-Equity has ranged from 3.28 to 40.07 over the past decade. While the company's 10-year median is 26.21 vs. the industry median of 7.78, Usana Health Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Consumer Packaged Goods company?
The median Return-on-Tangible-Equity among Consumer Packaged Goods companies is 7.78, based on 1,881 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Usana Health Sciences's current Return-on-Tangible-Equity of 10.40% is 33.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Usana Health Sciences and its competitors. For the Consumer Packaged Goods industry, the median Return-on-Tangible-Equity is 7.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Usana Health Sciences's current Return-on-Tangible-Equity is 10.40%, which is 60% below median its own 10-year median of 26.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Usana Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Usana Health Sciences (STU:USJ) is currently considered Possible Value Trap. The stock's GF Value™ is €35.51, compared to a current price of €18.90 — trading 46.8% below its estimated fair value. The current Return-on-Tangible-Equity is 10.40%, which is 60% below median its 10-year median of 26.21 and 33.7% above the Consumer Packaged Goods industry median of 7.78. Usana Health Sciences' overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Usana Health Sciences (STU:USJ), the current Return-on-Tangible-Equity is 10.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Usana Health Sciences (STU:USJ) Overvalued in 2026?
Based on GuruFocus' analysis, Usana Health Sciences stock appears to be undervalued.
The current stock price of €18.90 is trading 46.8% below its estimated GF Value™ of €35.51.
GuruFocus considers Usana Health Sciences to be Possible Value Trap.
Key valuation signals for STU:USJ:
Return-on-Tangible-Equity: 10.40% (60% below median its 10-year median of 26.21)
GF Value™: €35.51 vs. price of €18.90 (46.8% below fair value)
Industry Position: 33.7% above the Consumer Packaged Goods median (#1256 of 1881)
No single metric tells the full story. See the STU:USJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
67GF Score
Get the complete analysis for STU:USJ
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:USJ has been successfully added to your 
